Ladenburg Thalmann lifts Outlook Therapeutics Inc. [OTLK] price estimate. Who else is bullish?

Related

Share

Outlook Therapeutics Inc. [NASDAQ: OTLK] slipped around -0.29 points on Wednesday, while shares priced at $1.27 at the close of the session, down -18.59%. The company report on November 23, 2021 that Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 40,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 29, 2021, subject to satisfaction of customary closing conditions.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

Outlook Therapeutics Inc. stock is now -2.31% down from its year-to-date (YTD) trading value. OTLK Stock saw the intraday high of $1.27 and lowest of $1.19 per share. The company’s 52-week high price is 4.26, which means current price is +36.78% above from all time high which was touched on 02/09/21.

Compared to the average trading volume of 931.94K shares, OTLK reached a trading volume of 12573170 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Outlook Therapeutics Inc. [OTLK]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OTLK shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OTLK stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Ladenburg Thalmann have made an estimate for Outlook Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 11, 2019. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on May 16, 2019, representing the official price target for Outlook Therapeutics Inc. stock.

The Average True Range (ATR) for Outlook Therapeutics Inc. is set at 0.14 The Price to Book ratio for the last quarter was 15.87, with the Price to Cash per share for the same quarter was set at 0.11.

How has OTLK stock performed recently?

Outlook Therapeutics Inc. [OTLK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -33.16. With this latest performance, OTLK shares dropped by -40.09% in over the last four-week period, additionally sinking by -52.26% over the last 6 months – not to mention a rise of 2.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OTLK stock in for the last two-week period is set at 20.18, with the RSI for the last a single of trading hit 16.88, and the three-weeks RSI is set at 24.04 for Outlook Therapeutics Inc. [OTLK]. The present Moving Average for the last 50 days of trading for this stock 2.0792, while it was recorded at 1.4840 for the last single week of trading, and 2.2781 for the last 200 days.

Outlook Therapeutics Inc. [OTLK]: Deeper insight into the fundamentals

When it comes to the capital structure of this company, Outlook Therapeutics Inc. [OTLK] has a Total Debt to Total Equity ratio set at 170.78. Additionally, OTLK Total Debt to Total Capital is recorded at 63.07, with Total Debt to Total Assets ending up at 24.46. Long-Term Debt to Equity for the company is recorded at 33.50, with the Long-Term Debt to Total Capital now at 12.37.

Reflecting on the efficiency of the workforce at the company, Outlook Therapeutics Inc. [OTLK] managed to generate an average of -$4,404,937 per employee.Outlook Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.

Earnings analysis for Outlook Therapeutics Inc. [OTLK]

With the latest financial reports released by the company, Outlook Therapeutics Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -62.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OTLK.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Outlook Therapeutics Inc. [OTLK]

There are presently around $34 million, or 13.60% of OTLK stock, in the hands of institutional investors. The top three institutional holders of OTLK stocks are: BLACKROCK INC. with ownership of 5,838,612, which is approximately 1.472% of the company’s market cap and around 47.89% of the total institutional ownership; VANGUARD GROUP INC, holding 4,740,179 shares of the stock with an approximate value of $7.39 million in OTLK stocks shares; and LVW ADVISORS, LLC, currently with $2.72 million in OTLK stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Outlook Therapeutics Inc. stocks held by institutional investors increased at the end of December and at the time of the December reporting period, where 34 institutional holders increased their position in Outlook Therapeutics Inc. [NASDAQ:OTLK] by around 2,604,386 shares. Additionally, 22 investors decreased positions by around 1,572,331 shares, while 15 investors held positions by with 17,379,522 shares. The mentioned changes placed institutional holdings at 21,556,239 shares, according to the latest SEC report filing. OTLK stock had 8 new institutional investments in for a total of 1,439,861 shares, while 8 institutional investors sold positions of 157,246 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam